Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact

Comments for:

Phenotypic and pharmacogenetic evaluation of patients with thiazide-induced hyponatremia
James S. Ware, … , Ian P. Hall, Mark Glover
James S. Ware, … , Ian P. Hall, Mark Glover
Published August 7, 2017
Citation Information: J Clin Invest. 2017;127(9):3367-3374. https://doi.org/10.1172/JCI89812.
View: Text | PDF
Research Article Nephrology Therapeutics

Phenotypic and pharmacogenetic evaluation of patients with thiazide-induced hyponatremia

  • Text
  • PDF
Abstract

Thiazide diuretics are among the most widely used treatments for hypertension, but thiazide-induced hyponatremia (TIH), a clinically significant adverse effect, is poorly understood. Here, we have studied the phenotypic and genetic characteristics of patients hospitalized with TIH. In a cohort of 109 TIH patients, those with severe TIH displayed an extended phenotype of intravascular volume expansion, increased free water reabsorption, urinary prostaglandin E2 excretion, and reduced excretion of serum chloride, magnesium, zinc, and antidiuretic hormone. GWAS in a separate cohort of 48 TIH patients and 2,922 controls from the 1958 British birth cohort identified an additional 14 regions associated with TIH. We identified a suggestive association with a variant in SLCO2A1, which encodes a prostaglandin transporter in the distal nephron. Resequencing of SLCO2A1 revealed a nonsynonymous variant, rs34550074 (p.A396T), and association with this SNP was replicated in a second cohort of TIH cases. TIH patients with the p.A396T variant demonstrated increased urinary excretion of prostaglandin E2 and metabolites. Moreover, the SLCO2A1 phospho-mimic p.A396E showed loss of transporter function in vitro. These findings indicate that the phenotype of TIH involves a more extensive metabolic derangement than previously recognized. We propose one mechanism underlying TIH development in a subgroup of patients in which SLCO2A1 regulation is altered.

Authors

James S. Ware, Louise V. Wain, Sarath K. Channavajjhala, Victoria E. Jackson, Elizabeth Edwards, Run Lu, Keith Siew, Wenjing Jia, Nick Shrine, Sue Kinnear, Mahli Jalland, Amanda P. Henry, Jenny Clayton, Kevin M. O’Shaughnessy, Martin D. Tobin, Victor L. Schuster, Stuart Cook, Ian P. Hall, Mark Glover

×

Hyponatremia in patients on thiazides - SIADH vs. true TIH

Submitter: Anil Pareek | anil.pareek@ipca.com

Authors: Anil Pareek, Ravi T. Mehta, Indranil Purkait, and Anu Grover

Ipca Laboratories Ltd.

Published September 27, 2017

We read the research article with interest and complement the authors for shedding light on the pharmacogenetic aspects of thiazide-induced hyponatraemia (TIH)1. At the same time, we would like to pose certain queries to the authors so as to enable clinicians gain more insights from this research.

In practise, hyponatremia in patients on thiazides (either alone or with renin-angiotensin-aldosterone system inhibitors), usually occurs in the presence of precipitating events like CNS disorders, infections, etc. which may cause syndrome of inappropriate antidiuretic hormone secretion (SIADH). In such clinical situations, it is important to identify the induced SIADH before classifying it as TIH. Are there any phenotypic characteristics which can help clinicians distinguish hyponatremia due to the SIADH vs. TIH? Can the measurement of urine and plasma osmolality help differentiate the hyponatremia due to these two different etiologies?

The authors mention that hyponatremic patients who had relevant comorbidities were excluded. It will be worthwhile to know how many such patients with a relevant co-morbidity or precipitating event were excluded to get the strictly TIH patients and what were these common events. Further, amongst the patients with TIH included in the study, did the authors observe a dose-effect relationship between dose of thiazide used and the severity of hyponatremia? In a recent systematic review and meta-analysis of TIH, the average duration from thiazide initiation to diagnosis of TIH was 19 days (95% CI 8, 30 days); suggesting that the practice to measure serum biochemistry 1–2 weeks after thiazide initiation may not be appropriate2. What was the duration from thiazide initiation to diagnosis of TIH in the current study and whether this duration was different in the half of the TIH cases carrying the SLCO2A1 p.A396T variant?

Finally, the authors have demonstrated a phenotype resembling SIADH in these patients with TIH, but with low or normal ADH levels. If in these same patients, the ADH levels are high; can thiazides be ruled out as the cause of hyponatremia?

References:

1. Ware JS, Wain LV, Channavajjhala SK, et al. Phenotypic and pharmacogenetic evaluation of patients with thiazide-induced hyponatremia. J Clin Invest. 2017 Sep 1;127(9):3367-74.

2. Barber J, McKeever TM, McDowell SE, et al. A systematic review and meta-analysis of thiazide-induced hyponatraemia: time to reconsider electrolyte monitoring regimens after thiazide initiation? Br J Clin Pharmacol. 2015 Apr;79(4):566-77.


Response to Pareek and colleagues

Submitter: Mark Glover | Mark.Glover@nottingham.ac.uk

Queen's Medical Centre

Published September 27, 2017

Thank you for your E-letter and your interest in our study. We agree that it is important to consider other causes of hyponatremia in addition to thiazide diuretics and investigate appropriately in all patients who present to hospital with severe hyponatremia, both in research and clinical practise.

We also agree that SIADH remains an important differential diagnosis when considering the cause of hyponatremia in patients who take thiazide diuretics. Although in clinical practise it can be challenging to establish a single cause of hyponatremia, and in some cases hyponatremia may be multi-factorial, for the purposes of our study only patients with a clinical diagnosis of Thiazide-Induced Hyponatremia (TIH) were included. If there was any possibility of another cause for hyponatremia evident to either the clinical care team or researchers then the patient was not invited to participate. The exclusion criteria we used are detailed on supplementary page 31. For patients in cohort 2 we were also able to observe that serum sodium recovered to normal following cessation of the thiazide or thiazide-like diuretic.

Our study was not designed to investigate differences between TIH and SIADH in either phenotype or laboratory investigations of blood or urine. The measurement of plasma ADH was undertaken as a research test as part of this study, and is not often measured in routine clinical care in our hospital, and hence we cannot easily answer the question about distinguishing SIADH from TIH by phenotypic differences, although this would make an interesting subject for a future study.

The aetiology of hyponatremia amongst all patients presenting to our hospital has been studied previously 2 and in the current study our experience was similar in that many patients had other, multiple or unclear causes of hyponatremia: as discussed above these subjects were excluded from the study.  As the majority of subjects were given the same dose of thiazide, it is unclear if there is a dose response relationship between thiazide dose and risk of TIH. Unfortunately, we do not have precise data on the time from first thiazide dose to hospitalization with severe TIH and so cannot address whether the time course of TIH may differ in those who carry the SLCO2A1 p.A396T variant. A prospective study involving thiazide exposure would be better placed to address these issues.

References:

1. Ware JS, Wain LV, Channavajjhala SK, et al. Phenotypic and pharmacogenetic evaluation of patients with thiazide-induced hyponatremia. J Clin Invest. 2017 Sep 1;127(9):3367-74.

2. Clayton JA, Le Jeune IR, Hall IP. Severe hyponatraemia in medical in-patients: aetiology, assessment and outcome. QJM. 2006 Aug;99(8):505-11.

 

 

Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts